ScripTaisho Pharmaceutical Co., Ltd. has filed for the global first approval of its in-house oral dual orexin 1 and 2 receptor antagonist (DORA), vornorexant (development code TS-142), for insomnia in Jap
ScripTaisho Pharmaceutical Holdings, which owns one of Japan’s largest pharmaceutical firms, over-the-counter focused Taisho Pharmaceutical Co., Ltd. , initiated in late November what is set to be the lar
ScripJapan has given the first approval anywhere globally to Daiichi Sankyo Co., Ltd. ’s dual inhibitor of EZH1 (enhancer of zeste homolog 1) and EZH2 Ezharmia (valemetostat; DS-3201), for the treatment o
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seeking To Replicate Vraylar Success, A